Sage Therapeutics is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders
The company aims to address significant unmet medical needs by leveraging its expertise in neuroscience and advanced drug development. Sage Therapeutics is primarily engaged in the research and development of novel therapeutic compounds designed to target neurological and psychiatric conditions, such as major depressive disorder and epilepsy. Through its commitment to scientific rigor and patient-centered innovation, the company seeks to improve the lives of individuals affected by these challenging disorders.
Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis.
Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024.
Sage Therapeutics, Inc. (NASDAQSAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates.
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.
Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage” or “the Company”), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board intends to evaluate a broad range of opportunities to maximize value for shareholders, including but not limited to a potential strategic transaction, business combination or sale.
As 2025 kicks off, several companies are standing out as stocks to watch, driven by groundbreaking technologies, strategic market positioning, and strong growth potential. From cutting-edge oncology treatments to defense technology innovations and wellness solutions, these companies are making waves across various sectors. Here's a closer look at stocks like Phio Pharmaceuticals (NASDAQPHIO), LightPath Technologies NASDAQ: LPTHNASDAQLPTH)(NASDAQ: KAVLNASDAQKAVL, and more, making headlines and capturing investor attention.
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
Sage Therapeutics, Inc. (NASDAQSAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA.
Sage Therapeutics, Inc. (NASDAQSAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY.
